Termochilca avoided the execution of guarantees and initiated a sale process
January 2021 — The shareholders of Termochilca S.A. have completed a restructuring to avoid the execution of guarantees and to seek a solution that maximizes the value of the company.
Termochilca is engaged in the generation and commercialization of electric power. Its Santo Domingo de los Ollero thermal power plant began operations in October 2013 with an open cycle gas-fired power of 201 MW from the Camisea field. It currently has a capacity of 303 MW.
Our role in the transaction
Oaklins’ team in Chile negotiated with the creditors to avoid the execution of guarantees and supported Termochilca in this transaction.
Talk to the deal team
Related deals
Nexxtlab has successfully raised funding to support its growth
Nexxtlab, a Luxembourg-based energy technology company, has raised growth capital from an experienced international energy player. The investment marks an important milestone in Nexxtlab’s development and will support the company’s commercial expansion across Europe, continued product innovation and the further scaling of its energy management platform.
Learn moreLemvig Biogasanlæg has been acquired by BioticNRG
BioticNRG has acquired Lemvig Biogasanlæg A.M.B.A. in a transaction that expands its presence in the biogas sector and establishes a strategic platform for further growth in the Danish renewable energy market. The acquisition supports the continued development of Lemvig Biogasanlæg while strengthening the production of green gas in Denmark.
Learn moreEmpresa Eléctrica Cochrane has completed a corporate restructuring and liability management process
AES Andes S.A. has completed a corporate restructuring and liability management process that included the acquisition of Toesca’s indirect interest in Empresa Eléctrica Cochrane S.p.A. (Cochrane); the prepayment of Cochrane AES’s 5.50% 2027 international bond; the exchange of Cochrane’s BCOCH-A local bonds for new international bonds issued in Rule 144A/Regulation S format for US$485 million; and the merger between Cochrane and AES Andes.
Learn more